ArticleFrontiers in oncology2022

Case Report: Benefits of a NSCLC Patient With EGFR A289G/F287_G288insHA cis Mutations From Immunotherapy in Combination With Antiangiogenesis and Chemotherapy and Sequential Treatment of EGFR-TKI.

He Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.